Table 3.

Adjusted Hazard Ratios Based on Time to the Composite Event by Baseline Covariates and Treatment.

		RWP		DPP
		Hazard Ratioa	95% CI	Hazard Ratioa	95% CI
Sex	Male	1.07	0.81–1.41	0.98	0.72–1.35
Age	60–69	1.23	0.76–2.01	1.31	0.75–2.29
	70–79	1.38	0.85–2.21	1.44	0.83–2.50
	≥80	1.37	0.83–2.26	1.42	0.80–2.53
BMI	<18.5	1.40	0.95–2.07	1.25	0.79–1.99
	18.5–24.9	1.32	1.01–1.74	1.38	1.01–1.90
Fontaine Classification	Stage II	1.49	1.13–1.98	0.93	0.61–1.42
	Stage III	1.64	1.09–2.46	0.85	0.49–1.49
	Stage IV	4.22	2.92–6.10	2.86	1.76–4.64
ABPIb	0.99–0.90	1.01	0.61–1.67	—	—
	0.89–0.70	1.36	0.93–2.00	0.79	0.48–1.28
	0.69–0.40	1.58	1.07–2.34	0.84	0.52–1.36
	<0.40	2.42	1.51–3.88	1.29	0.74–2.24
Smoking	Past smoker	1.09	0.82–1.45	0.97	0.70–1.35
	Current smoker	1.45	1.06–1.99	1.47	1.03–2.09
History/Complication	Hypertension	1.20	0.91–1.58	1.13	0.83–1.54
	Diabetes mellitus	1.31	1.06–1.63	1.35	1.06–1.73
	Chronic kidney disease	2.00	1.59–2.52	1.86	1.43–2.43
	Heart disease	1.41	1.12–1.78	1.29	0.99–1.68
	Cerebrovascular disease	1.18	0.92–1.51	1.22	0.93–1.62
Medication	Sarpogrelate	0.93	0.71–1.21	0.98	0.72–1.32
Combined Medications	Aspirin	0.92	0.73–1.16	0.83	0.64–1.08
	Antiplatelets other than aspirin	1.11	0.89–1.39	1.09	0.85–1.39
	Statin	1.02	0.82–1.27	1.07	0.83–1.38

Abbreviations: ABPI, ankle-brachial pressure index; BMI, body mass index; CI, confidence interval; DPP, definite peripheral arterial disease population; RWP, real-world population.

^aHazard ratio adjusted for sex, age, BMI, Fontaine classification, ABPI, smoking, history/complication (hypertension, diabetes mellitus, chronic kidney disease, heart disease, cerebrovascular disease), medication (sarpogrelate), combined medications (aspirin agents, other antiplatelet agent except aspirin, statin).

References for hazard ratios: sex (female), age (under 60), BMI (≥25), Fontaine classification (Stage I), ABPI (≥1.0 for RWP and ≥0.90 for DPP), smoking (non-smoker), history/complication (without each history/complication), medication (cilostazol, ticlopidine, prostaglandin I₂, prostaglandin E₁, or eicosapentaenoic acid), combined medications (without each agent).

^bCompared with ABPI ≥1.00 in the RWP and compared with ABPI ≥0.90 in DPP.